Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial
Open Access
- 10 February 2018
- journal article
- research article
- Published by Elsevier BV in The Lancet Oncology
- Vol. 19 (3), 405-415
- https://doi.org/10.1016/s1470-2045(18)30081-0
Abstract
No abstract availableKeywords
Funding Information
- Pfizer
This publication has 31 references indexed in Scilit:
- Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2 (VEGFR2) induces synergistic anti-tumour effect in vivoClinical and Experimental Immunology, 2013
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerThe New England Journal of Medicine, 2012
- Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trialThe Lancet, 2011
- Diastolic Blood Pressure as a Biomarker of Axitinib Efficacy in Solid TumorsClinical Cancer Research, 2011
- Molecular Mechanisms of Resistance to Tumour Anti-Angiogenic StrategiesJournal of Oncology, 2010
- Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter StudyJournal of Clinical Oncology, 2009
- Tumor antigen–specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impairedBlood, 2009
- Modes of resistance to anti-angiogenic therapyNature Reviews Cancer, 2008
- Inhibitory B7-family molecules in the tumour microenvironmentNature Reviews Immunology, 2008
- Anti‐angiogenesis therapy can overcome endothelial cell anergy and promote leukocyte‐endothelium interactions and infiltration in tumorsThe FASEB Journal, 2006